Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
106-120 of 2360 results
Aytu BioScience buys US commercial rights to Natesto Nasal Gel
Aytu BioScience has executed a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals for the U.S. commercial rights to Natesto (testosterone) Nasal Gel.
Contract Research & Services > Contract Services > News
Immune Therapeutics signs binding LoI to acquire Chinese CAR-T technology and clinical data
Immune Therapeutics has signed a binding Letter of Intent (LoI) to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data of the aforementioned therapies from Super-T Cell Cancer Company ("STCC") a newly formed corporation.
Contract Research & Services > Contract Services > News
OncBioMune signs deal with Vitel to form JV to develop cancer therapies
OncBioMune Pharmaceuticals has signed a contract to form a Joint Venture (JV) with Vitel Laboratorios to develop and commercializie OncBioMune's portfolio of innovative cancer therapies in Mexico and Latin America.
Contract Research & Services > Contract Services > News
Evotec, Pierre Fabre sign multi-year compound management deal
Evotec has signed a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.
Contract Research & Services > Contract Services > News
Enumeral, Pieris Pharmaceuticals sign license and transfer agreement
Enumeral Biomedical has entered into a License and Transfer Agreement with Pieris Pharmaceuticals and Pieris Pharmaceuticals (collectively, Pieris).
Contract Research & Services > Contract Services > News
NewLink Genetics secures $2.8m award from DTRA to develop multivalent filovirus vaccine
The Defense Threat Reduction Agency (DTRA) of the United States Department of Defense has awarded a subsidiary of NewLink Genetics a $2.8m base contract with potential future options totaling $6.3m to support the development of vaccines against filovirus species including Marburg and Ebola Sudan viruses, which could be combined with Ebola Zaire virus in a multivalent vaccine formulation or vaccination schedule.
Contract Research & Services > Contract Services > News
Akari Therapeutics, XL-protein sign license deal to develop long acting version of Coversin
Akari Therapeutics and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement.
Contract Research & Services > Contract Services > News
Aires Pharmaceuticals inks deal with Duke University for Phase 2 study of AIR001 in HFpEF patients
Mast Therapeutics' subsidiary, Aires Pharmaceuticals, has entered into an agreement with Duke University to provide support for a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study of the Company's product candidate AIR001 in patients with heart failure with preserved ejection fraction (HFpEF).
Contract Research & Services > Contract Services > News
Oncternal Therapeutics secures worldwide license to ROR1 antibody from UC San Diego
Oncternal Therapeutics has received an exclusive worldwide license to develop and commercialize antibodies and antibody-related binding agents recognizing Receptor-tyrosine kinase-like orphan receptor 1 (ROR1) from University of California San Diego.
Contract Research & Services > Contract Services > News
EUSA Pharma acquires global rights to Arcoral Tab from Arcoral Pharma
EUSA Pharma has acquired the global rights to a next generation formulation of EUSA's current Caphosol product from Arcoral Pharma.
Contract Research & Services > Contract Services > News
Tobira Therapeutics, Dong-A ST sign license agreements for Evogliptin and Cenicriviroc
Tobira Therapeutics and Dong-A ST Co. have entered into two separate licensing agreements.
Contract Research & Services > Contract Services > News
NMT Pharmaceuticals inks licensing deal with CAO Pharma on anti-cancer drug CZ-48
NMT Pharmaceuticals has signed a licensing agreement with US-based CAO Pharmaceuticals (CAO Pharma) for an exclusive worldwide license right to further develop and market an anti-cancer drug CZ-48 co-developed by CAO Pharma and NMT Pharma.
Contract Research & Services > Contract Services > News
Eisai, PharmStandard sign cooperation agreements in Russia
Japanese research and development pharmaceutical firm Eisai and Russia-based PharmStandard have signed cooperation agreements relating to the localised production of Eisai products in Russia.
Contract Research & Services > Contract Services > News
NantBioScience, NantKwest partner with NCI to further develop recombinant NK cells and monoclonal antibodies
NantBioScience has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the National Institutes of Health (NIH).
Contract Research & Services > Contract Services > News
Portola Pharmaceuticals inks deal with Daiichi Sankyo to develop andexanet alfa with edoxaban
Portola Pharmaceuticals has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor, in Japan.
Contract Research & Services > Contract Services > News
106-120 of 2360 results